On August 7, 2023 Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, reported that the company has joined the ctMoniTR Project, a collaborative research initiative providing foundational evidence to inform future use of change in circulating tumor DNA (ctDNA) as an early indicator of long-term clinical benefit from therapeutics in cancer patients (Press release, Gritstone Bio, AUG 7, 2023, View Source [SID1234633873]). The ctMoniTR Project is led by Friends of Cancer Research (Friends).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"ctDNA represents a highly promising biomarker that could transform the way we develop novel cancer immunotherapies," said Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief Executive Officer of Gritstone bio. "As cancer drug development has evolved, the field has seen the immense impact that biomarkers can offer when it comes to identifying effective novel treatments early on, which can make an enormous difference in the lives of patients. We’re pleased to serve as a partner on the ctMoniTR Project, which will help empirically inform the clinical applications where ctDNA exhibits the greatest potential to accelerate novel drug development."
Through the ctMoniTR Project, Gritstone and other partners contribute data and collaborate with Friends to help develop data-driven evidence of how ctDNA can inform treatment decisions, support drug development, and inform regulatory decision-making. To date, Friends and its partners have collected data from more than 25 studies representing over 3,000 cancer patients, 16 additional treatments, and several cancer types.
"The use of ctDNA as a tool to predict clinical outcomes with novel forms of immunotherapy is accelerating at a rapid pace, and the data emerging from this growing field point to ctDNA potentially serving as a more precise and accurate predictor of outcomes than current radiology-based measures," added Karin Jooss, Ph.D., Executive Vice President and Head of R&D at Gritstone. "Through ctMonitor, we aim to help the field better understand and validate this new, powerful tool. We are thankful to Friends for their leadership of this unique project and hope our collective efforts can help bring new therapies to patients safely and efficiently."
For more information on the ctMoniTR Project, visit: View Source